Can you take cannabis with sleep medications?

Cannabis and sleep medications interact through two mechanisms. First, both cannabis (THC and CBD) and sleep medications (benzodiazepines, Z-drugs) produce CNS depression — sedation. Combined use produces additive sedation beyond what either substance alone would cause. Second, CBD inhibits CYP3A4, the primary metabolic enzyme for benzodiazepines and Z-drugs (zolpidem, eszopiclone), raising their blood levels above the prescribed dose. The combination of higher drug levels and additive CNS depression significantly increases sedation and falls risk, particularly in older adults. Prescriber disclosure is strongly recommended.

Is it safe to use melatonin and cannabis together?

Melatonin and cannabis carry lower interaction concern than benzodiazepines or Z-drugs with cannabis, but the combination still warrants awareness. Both melatonin and cannabis (particularly THC) have sedative properties — their combination may produce more sedation than intended. Melatonin is not significantly CYP3A4 metabolized, so the pharmacokinetic interaction with CBD is less relevant. The primary concern is additive sedation. Melatonin's therapeutic window is wide, so accumulation from enzyme inhibition is less of a clinical concern than with prescription sleep medications. Prescriber awareness of the combination is still prudent, especially in older adults.

Does cannabis help with sleep?

Some people report THC improves sleep initiation, and some research supports this for short-term use. However, THC suppresses REM sleep — the stage associated with dreaming and cognitive restoration. Long-term cannabis use as a sleep aid can alter sleep architecture, and cannabis-dependent sleep often worsens after discontinuation (rebound insomnia). Cannabis for sleep is not FDA-approved and is not a pharmacist-recommended alternative to evidence-based sleep treatments. This information is provided for context — patients using cannabis for sleep in addition to prescribed sleep medications should discuss both with their prescriber to avoid additive sedation risks.

Cannabis & Sleep Medications: CNS Depression, CYP3A4, Benzodiazepines, Z-Drugs

Two Interaction Pathways

Mechanism Overview

Additive CNS Depression

Both cannabis (THC and CBD) and prescription sleep medications produce central nervous system depression — sedation. This is a pharmacodynamic interaction: the two substances act on overlapping CNS pathways, with their sedative effects adding together. When cannabis is used the same evening as a sleep medication, sedation may be substantially deeper than the prescription alone was designed to produce. NIH NCCIH

The depth of additive sedation depends on the cannabis product's THC and CBD content, the specific sleep medication and dose, and individual patient factors. There is no threshold below which the additive effect can be assumed negligible without clinical assessment.

CYP3A4 Inhibition Raises Drug Levels

Benzodiazepines (lorazepam, diazepam, clonazepam, temazepam) and Z-drugs (zolpidem/Ambien, eszopiclone/Lunesta, zaleplon/Sonata) are metabolized primarily by CYP3A4. CBD and THC inhibit this enzyme. FDA Epidiolex PI The result: these sleep medications are cleared more slowly when cannabis is co-used, causing drug plasma levels to rise. Higher drug levels plus additive sedation from cannabis creates a two-pathway amplification of sedation and adverse effect risk.

Sleep Medication Risk Profiles

By Drug Class

Medication	Brand	Enzyme	Cannabis Interaction
Zolpidem	Ambien	CYP3A4 (primary)	⚠️ Caution — CYP3A4 inhibition by CBD raises zolpidem levels; additive sedation; next-day impairment risk
Eszopiclone	Lunesta	CYP3A4 (primary)	⚠️ Caution — same CYP3A4 profile as zolpidem; combined use may cause excessive morning sedation
Zaleplon	Sonata	CYP3A4 (minor), aldehyde oxidase (primary)	🔵 Moderate — less CYP3A4 dependent than zolpidem; additive sedation still applies
Lorazepam	Ativan	Glucuronidation (minimal CYP)	🔵 Moderate — not primarily CYP3A4; pharmacokinetic risk lower than zolpidem. Additive CNS depression is primary concern.
Diazepam	Valium	CYP2C19, CYP3A4	⚠️ Caution — CYP3A4 involvement adds pharmacokinetic concern to additive CNS depression. Long half-life amplifies accumulation risk.
Clonazepam	Klonopin	CYP3A4 (primary reduction pathway)	⚠️ Caution — CYP3A4 substrate; CBD inhibition may raise clonazepam levels; long half-life creates accumulation concern
Temazepam	Restoril	Glucuronidation (minimal CYP)	🔵 Moderate — minimal CYP involvement; pharmacokinetic risk lower. Additive sedation remains the primary concern.
Melatonin	Melatonin (OTC)	CYP1A2 (primary)	✓ Lower Risk — not significantly CYP3A4 metabolized. Additive sedation is modest. Lower risk than prescription sleep medications.

Falls Risk: The Most Serious Practical Consequence

Older Adults at Highest Risk

For adults over 65, excessive sedation from cannabis combined with sleep medications translates directly to falls risk — one of the most consequential adverse outcomes in geriatric medicine.

Nocturnal Falls

If sedation depth exceeds normal sleep medication levels, an older adult waking at night to use the bathroom may not have adequate motor coordination and spatial awareness. Nighttime falls in older adults cause fractures — including hip fractures — that carry serious morbidity and mortality consequences.

Morning Carry-Over Sedation

When CYP3A4 inhibition by CBD raises sleep medication levels, drug activity may extend well past the intended sleep window into morning hours. Next-day sedation, cognitive impairment, and motor instability can affect driving safety and fall risk throughout the following day — not just during sleep hours.

Age-Related Pharmacokinetic Amplification

Older adults have reduced hepatic CYP450 activity as a baseline — meaning sleep medications already clear more slowly with age. Adding CBD's CYP3A4 inhibition to already-slower clearance amplifies this effect more than in younger adults. The drug accumulation problem from CYP inhibition is proportionally larger in older patients.

Cannabis and Sleep: What the Evidence Shows

Clinical Context

Some patients use cannabis specifically for sleep and are prescribed sleep medications simultaneously. Understanding both the potential benefit and the interaction risk is clinically relevant.

THC and Sleep Architecture

THC has been shown in research to reduce the time to sleep onset and may decrease nighttime awakenings in the short term. However, THC suppresses REM (rapid eye movement) sleep — the sleep stage associated with memory consolidation and emotional processing. Chronic use alters sleep architecture, and discontinuation of THC is associated with rebound insomnia and vivid dreams as REM sleep rebounds. Cannabis is not an FDA-approved sleep treatment and is not a pharmacist-recommended primary intervention for insomnia. NIH NCCIH

For patients already on prescribed sleep medications who are also using cannabis for sleep: the combination is not typically necessary from an efficacy standpoint, creates real interaction risk, and should be discussed with the prescriber — who may recommend evidence-based alternatives (CBT-I, cognitive behavioral therapy for insomnia) that do not carry drug interaction risk.

Frequently Asked Questions

Common Queries

Can I take cannabis and Ambien together? ▼

The combination of cannabis and zolpidem (Ambien) carries real risk. Zolpidem is metabolized by CYP3A4, which CBD inhibits — raising zolpidem blood levels above the prescribed dose. Additionally, both cannabis and zolpidem produce CNS depression that adds together. The combined result can be deeper sedation than intended, impaired motor coordination if awakened, and next-day cognitive and motor carry-over effects. Zolpidem already carries an FDA boxed warning about complex sleep behaviors and next-day impairment — cannabis amplifies these risks. This is not a blanket prohibition, but it is a combination that requires prescriber awareness and explicit discussion about timing and dose.

Can I use melatonin and cannabis on the same night? ▼

Melatonin and cannabis represent a lower-concern combination compared to benzodiazepines or Z-drugs with cannabis. Melatonin's primary metabolic enzyme is CYP1A2 — not significantly inhibited by cannabinoids — so the pharmacokinetic interaction is minimal. Both have mild-to-moderate sedative effects that may add together, but melatonin's sedative profile is substantially weaker than prescription sleep medications, and melatonin's therapeutic window is very wide. The combination is considered lower risk than prescription sleep medication combinations, but prescriber awareness is still reasonable — particularly in older adults taking multiple other medications.

I use cannabis because my sleep medications stopped working. What should I know? ▼

If you are using cannabis in addition to (or instead of) prescribed sleep medications, your prescriber should know this. First, cannabis interacts with the sleep medications — raising their levels and adding sedation. Second, tolerance to sleep medications and cannabis sleep benefits are both real phenomena. Third, the most effective long-term treatment for insomnia is cognitive behavioral therapy for insomnia (CBT-I) — a structured program that does not involve medication and has better long-term outcomes than either sleep medications or cannabis for chronic insomnia. Many prescribers can refer to CBT-I programs, and digital CBT-I tools are increasingly available. Discussing sleep quality that is not responsive to current medication management with your prescriber — including cannabis use context — allows a more complete clinical assessment.

Does CBD help with sleep differently than THC? ▼

CBD and THC have different effects on sleep. THC is more directly sedating — it reduces sleep onset latency and suppresses REM sleep. CBD's effects on sleep are less characterized; at lower doses, some research suggests CBD may have wake-promoting effects rather than sedating effects, while at higher doses CBD may be mildly sedating. The interaction concern with sleep medications is different for CBD vs THC: CBD's primary interaction is pharmacokinetic (CYP3A4 inhibition raising sleep drug levels), while THC's primary interaction is pharmacodynamic (additive CNS depression). Full-spectrum cannabis products containing meaningful amounts of both add both interaction pathways.

👨‍⚕️ Clinical Reviewer

Sanford A. Orloff, RPh (ret.)

Registered Pharmacist · 40+ Years Clinical Experience · NPI: 1518289974
View credentials → · Verify NPI →

📚

Primary Sources

FDA. Epidiolex (cannabidiol) Prescribing Information. NDA 210365. CYP3A4 inhibition by CBD; sections on CNS depressant interactions.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210365s006lbl.pdf
NIH NCCIH. "Cannabis (Marijuana) and Cannabinoids: What You Need To Know." Updated December 2021. Sections covering CNS depression additive effects and drug interactions.
https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know
NIH MedlinePlus. Zolpidem; Eszopiclone; Lorazepam; Diazepam; Clonazepam Drug Information. National Library of Medicine. Metabolism, CNS depression warnings, and interaction documentation.
https://medlineplus.gov/druginformation.html
Stout SM, Cimino NM. "Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review." Drug Metabolism Reviews. 2014;46(1):86-95. PMID: 24160757.
https://doi.org/10.3109/03602532.2013.849268
FDA. Ambien (zolpidem) Prescribing Information. Boxed warning on complex sleep behaviors; drug interaction sections including CNS depressants. Sanofi-Aventis.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019908s031lbl.pdf